

325 Binney Street, Cambridge, MA 02142
617-714-6500
617-583-1999

Update on the mRNA-3927 Clinical Program: Enrollment Completed in Part 2 of the Paramount Trial and Recordati Partnership

24 February 2026

Disclaimer: This communication is intended to provide general information to the PA community and is not intended to promote any investigational or approved treatment.

Dear Acidemia/Aciduria Community,


We are pleased to share that Part 2 of the Paramount trial (mRNA-3927P101), evaluating the investigational treatment mRNA-3927 for propionic acidemia/aciduria (PA), has completed enrollment. Enrollment in Part 3 of the Paramount trial is still ongoing.

The Paramount trial is a Phase 1/2 clinical trial designed to evaluate the safety and effectiveness of mRNA-3927, an investigational treatment intended to address the underlying Propionyl-CoA carboxylase (PCC) enzyme deficiency in PA. The trial is made up of 3 Parts, each of which started at different times:

- **Part 1:** was designed to evaluate the safety of mRNA-3927 and help determine optimal doses for Parts 2 and 3. Part 1 enrolled individuals ≥ 1 year old and has already been completed.
- **Part 2:** was designed to evaluate the safety and effectiveness of specific doses of mRNA-3927 based on the findings from Part 1. Part 2 enrolled individuals ≥ 1 year old and has completed enrollment.
- **Part 3:** was designed to evaluate the safety of mRNA-3927 and help determine optimal doses in individuals who are < 1 year old. Part 3 is ongoing and actively recruiting participants that meet specific eligibility criteria.

With enrollment now complete for Part 2 of the trial, the mRNA-3927 program is progressing as planned. On January 29, 2026, Moderna announced (subject to antitrust approval) a commercialization partnership with Recordati Industria Chimica e Farmaceutica S.p.A. to support the future global commercialization of mRNA-3927.

We want to express our sincere gratitude to the entire PA community, including people living with PA, families, advocacy organizations, researchers, healthcare providers, and dedicated investigators, whose ongoing commitment and collaboration continue to support this program.



325 Binney Street, Cambridge, MA 02142
617-714-6500
617-583-1999

Moderna is committed to advancing the understanding of PA in collaboration with the community. We will keep the community informed of significant developments as they are finalized and look forward to sharing further updates.

With deep appreciation,
The Moderna Rare Disease Team

Questions & Answers:

Can I still join the Paramount trial?


- Thank you for your interest in the Paramount trial. Enrollment for Part 2 of the study is now complete, so new participants can no longer join this part of the trial.
- Part 3 of the Paramount trial is still ongoing and actively enrolling infants under 1 year of age who meet specific eligibility criteria. Please consult your healthcare provider if you have an interest in learning more and to determine whether a clinical trial is right for your family.

When will the Paramount trial finish?

- Part 2 of the Paramount trial has completed enrollment. Participants in Part 2 will undergo a 12-month treatment evaluation period, which is the time during the trial when participants receive mRNA-3927. After all participants finish this period, we anticipate Part 2 of the trial will conclude in 2026.
- Part 3 will continue to enroll and run in parallel even as Part 2 concludes.

When will results from the trial be available?

- Although Part 2 of the trial is fully enrolled, participants must complete their time in the study before we can begin analyzing results. The study follows each participant for 12 months, and we aim to begin data analysis after follow-ups for all participants are completed. We will share results with the community as they become available.



325 Binney Street, Cambridge, MA 02142
617-714-6500
617-583-1999

What is the difference between the Paramount and mRNA-3927-P101 EXTENSION trials?

- The Paramount trial is a Phase 1/2 clinical trial evaluating the safety, dosing, and effectiveness of mRNA-3927 in PA. The trial is also known as mRNA-3927P101.
- In the mRNA-3927P101 EXTENSION trial, participants who completed the Paramount trial may continue receiving mRNA-3927. Its goal is to evaluate the long-term safety of mRNA-3927 in PA. Enrollment in the mRNA-3927P101 EXTENSION trial is optional.

Where can I learn more about your trial?

- Please visit clinicaltrials.gov for more information regarding these trials.

When do you expect mRNA-3927 to be approved and available?

- Once Part 2 is complete, we will evaluate the results and engage with global health regulatory agencies, such as the US Food & Drug Administration (FDA), to determine next steps. We will continue to provide updates to the community as more information becomes available.

What does the commercialization partnership with Recordati mean?

- Moderna has entered into a strategic collaboration with Recordati to support the global commercialization of mRNA-3927. Moderna will continue to lead clinical development through approval and Recordati will lead commercialization.
- The announcement of this collaboration does not affect the ongoing clinical trial. As the partnership progresses, we plan to share additional details when available.